• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioAtla Inc. (Amendment)

    2/6/24 3:57:34 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    SC 13G/A 1 p24-0352sc13ga.htm BIOATLA, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    BioAtla, Inc.

    (Name of Issuer)
     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)
     

    09077B104

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 09077B10413G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Bioventures, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,824,918

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,824,918

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,824,918

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

    CUSIP No. 09077B10413G/APage 3 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Capital Advisors GP, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,824,918

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,824,918

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,824,918

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 09077B10413G/APage 4 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Bioventures 2 L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,207,128

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,207,128

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,207,128

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.6%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    CUSIP No. 09077B10413G/APage 5 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Capital Advisors GP 2, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,207,128

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,207,128

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,207,128

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.6%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 09077B10413G/APage 6 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Anders Hove

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,032,046

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,032,046

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,032,046

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.4%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 09077B10413G/APage 7 of 10 Pages

     

    Item 1(a). Name of Issuer:
       
      BioAtla, Inc. (the "Issuer")

     

    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    11085 Torreyana Road

    San Diego, California 92121

     

    Item 2(a). Name of Person Filing:
       
      This statement is filed by:
       
      (i) Acorn Bioventures, L.P. (“Acorn”);
      (ii) Acorn Capital Advisors GP, LLC (“Acorn GP”), which is the sole general partner of Acorn;
      (iii) Acorn Bioventures 2, L.P. (“Acorn 2”);
      (iv) Acorn Capital Advisors GP 2, LLC (“Acorn GP 2”), which is the sole general partner of Acorn 2; and
      (v) Anders Hove (“Hove or “Manager”).
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  
       
    Item 2(b). Address of Principal Business Office:
       
      The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170
       
    Item 2(c). Place of Organization:
       
      Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Acorn 2 is a Delaware limited partnership. Acorn GP 2 is a Delaware limited liability company. Each of Hove and Manke are citizens of the United States of America.

     

    Item 2(d). Title of Class of Securities:
       
      Common stock, $0.0001 par value per share (the "Common Stock")

     

    Item 2(e). CUSIP Number:
       
      09077B104

     

     

    CUSIP No. 09077B10413G/APage 8 of 10 Pages

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) o

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                     

     

    Item 4. Ownership:
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  
       
      The percentages set forth herein are calculated based upon 47,935,808 shares of Common Stock outstanding as of November 6, 2023 as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 13, 2023.
       

     

    CUSIP No. 09077B10413G/APage 9 of 10 Pages

     

      Acorn GP is the general partner of Acorn and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn.  Acorn GP 2 is the general partner of Acorn 2 and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn 2.
       
      The Manager, in his capacity as manager of each of Acorn GP and Acorn GP 2, may be deemed to beneficially own the shares beneficially owned by each of Acorn and Acorn 2.

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
       
      Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group:
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group:
       
      Not applicable.

     

    Item 10. Certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 09077B10413G/APage 10 of 10 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  February 6, 2024  
      ACORN BIOVENTURES, L.P.
      By: ACORN CAPITAL ADVISORS GP, LLC, its General Partner
      By:  /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ACORN CAPITAL ADVISORS GP, LLC
      By:  /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ACORN BIOVENTURES 2, L.P.
      By: ACORN CAPITAL ADVISORS GP 2, LLC, its General Partner
      By:  /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ACORN CAPITAL ADVISORS GP 2, LLC
      By:  /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ANDERS HOVE
      /s/ Anders Hove
       

     

    Get the next $BCAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    8/13/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Waldron Richard A covered exercise/tax liability with 2,371 shares, decreasing direct ownership by 0.68% to 346,150 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/1/25 6:37:25 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Sievers Eric covered exercise/tax liability with 2,729 shares, decreasing direct ownership by 0.75% to 361,845 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/1/25 6:35:22 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 6,347 shares, decreasing direct ownership by 0.28% to 2,237,331 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/1/25 6:35:06 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    SEC Filings

    View All

    SEC Form DEF 14A filed by BioAtla Inc.

    DEF 14A - BioAtla, Inc. (0001826892) (Filer)

    12/5/25 4:05:09 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by BioAtla Inc.

    PRE 14A - BioAtla, Inc. (0001826892) (Filer)

    11/24/25 8:00:14 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by BioAtla Inc.

    424B5 - BioAtla, Inc. (0001826892) (Filer)

    11/21/25 8:33:34 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

    These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year endThese agreements ensure BioAtla can maintain operational momentum while completing that process SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into Pre-paid Advance Agreements with a

    11/21/25 12:25:45 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

    Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half of 2026Achieved milestone with Context Therapeutics under the license agreement for the CAB-Nectin4-TCE reflecting continued progress and validation of BioAtla's differentiated CAB T-cell

    11/13/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

    — Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced clinical data in a poster t

    11/7/25 9:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    1/19/24 4:21:50 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/26/23 7:43:02 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/20/23 6:27:44 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioAtla downgraded by Citizens JMP

    Citizens JMP downgraded BioAtla from Mkt Outperform to Mkt Perform

    8/13/25 8:01:09 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla downgraded by H.C. Wainwright

    H.C. Wainwright downgraded BioAtla from Buy to Neutral

    11/13/24 7:31:56 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    JMP Securities initiated coverage on BioAtla with a new price target

    JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00

    9/15/22 7:31:28 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

    SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

    11/14/24 4:00:05 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

    SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

    10/2/24 4:30:04 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

    SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

    9/6/24 4:59:38 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Financials

    Live finance-specific insights

    View All

    BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

    Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half of 2026Achieved milestone with Context Therapeutics under the license agreement for the CAB-Nectin4-TCE reflecting continued progress and validation of BioAtla's differentiated CAB T-cell

    11/13/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

    SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, November 13, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2025 Earnings Conference CallDial-in Numbers: (800)-343-4136 (domestic), (203) 518-9843 (internation

    11/5/25 8:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

    CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management to host conference call and webcast today at 4:30 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology co

    8/7/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    View All

    BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

    SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

    12/21/21 9:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care